NCT03895502View on ClinicalTrials.gov

Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

PHASE4CompletedINTERVENTIONAL

Enrollment

605

Participants

Timeline

Start Date

May 27, 2019

Primary Completion Date

June 30, 2023

Study Completion Date

August 31, 2023

Conditions

Venous ThrombosisNeoplasmsAnticoagulant

Interventions

DRUG

12-month Edoxaban

Prescription of Edoxaban for 12 months

DRUG

3-month Edoxaban

Prescription of Edoxaban for 3 months

Trial Locations (1)

606-8507

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

All Listed Sponsors

lead

Takeshi Morimoto

OTHER

NCT03895502 - Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study | Biotech Hunter | Biotech Hunter